PEDIATRIC AND ADULT INFLUENZA WEBINAR: 2022-2023 FLU SEASON SEPTEMBER 7, 2022


PRESENTERS: SHELLY DOEBLER, MPH ANDREA BECKER, BSN, RN





INSTRUCTIONS FOR WEBINAR PARTICIPATION

- The webinar will start at 12:00 PM EDT
- Audio is through your computer speakers or headset – you may not hear sound until the webinar begins
- Audio check use Audio Settings to test speaker or headset



 This webinar is being recorded and a link will be provided to registrants within 48 hours

How to Ask **Questions**

- I. Click on the icon found at the bottom part of your screen
- 2. A box will open where you can type in questions, comments, indicate sound problems, etc.
- 3. Use this throughout the webinar to ask questions

Technical Help

 Telephone (844) 678-6200 for technical support



SPEAKER DISCLOSURES

- Speakers for today's webinar:
 - Andrea Becker, BSN, RN, Immunization Nurse Educator, MDHHS
 - Shelly Doebler, MPH, Influenza Epidemiologist, MDHHS
- All faculty presenters have nothing to disclose.
- No commercial support was provided for this CME/PCE activity.



CME INFORMATION

- This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MSU and MDHHS. MSU is accredited by the ACCME to provide continuing education for physicians.
- Michigan State University designates this live activity for a maximum of 1.0 AMA PRA Category I Credit[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



PCE INFORMATION

- This activity has been approved to meet knowledge-based educational needs and 1.0 Pharmacy Continuing Education (PCE) Credit will be awarded to participants by the Michigan Pharmacists Association (MPA).
- Michigan Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.



PEDIATRIC AND ADULT INFLUENZA WEBINAR OBJECTIVES

- Discuss influenza disease rates, surveillance, and vaccine coverage levels
- Discuss influenza vaccine recommendations
- Identify strategies to improve influenza vaccination rates






INFLUENZA DISEASE BURDEN

- Difficult to predict severity and timing
- Rates of serious illness and death greatest in:
 - Persons aged 65 years and older
 - Children <5 years, especially children less than 2 years of age
 - Persons with medical conditions that put them at high risk
- Only half develop classic clinical flu symptoms
- 5 categories of surveillance: viral, mortality, hospitalization, geographic spread, and outpatient influenza-like illness (ILINet)²
 - We need more ILINet providers!
 - For more information email, <u>DoeblerM@michigan.gov</u>





INFLUENZA-ASSOCIATED PEDIATRIC DEATHS

- Became nationally reportable in 2004 for people younger than 18 years of age
- 2021-2022: 33 flu-associated pediatric deaths reported
- 2019-2020 flu season: 199 pediatric deaths
- "Influenza-Associated Pediatric Deaths in the United States, 2010–2016²"
 - Published February 2018
 - Average annual number: 113
 - Highest incident rate among children < 6 months (0.66 per 100,000)</p>
 - 65% died within a week of symptom onset
 - Half had no pre-existing medical conditions
 - Only 31% of children \geq 6 months had received any flu vaccinations




- 1. www.cdc.gov/flu/weekly/index.htm#lLIMap
- 2. https://pediatrics.aappublications.org/content/141/4/e20172918

2022-2023 INFLUENZA VACCINATION STRAINS

- Egg-based vaccines will include:
 - an A/Victoria/2570/2019 (HINI)pdm09-like virus;
 - an A/Darwin/9/2021 (H3N2)-like virus (NEW);
 - a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (NEW);
 - a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (Quadrivalent only)
- Quadrivalent cell- or recombinant-based vaccines will include:
 - an A/Wisconsin/588/2019 (HINI)pdm09-like virus;
 - an A/Darwin/6/2021 (H3N2)-like virus (NEW);
 - a B/Austria/1359417/2021 (B/Victoria lineage)-like virus (NEW);
 - a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus



www.who.int/news/item/25-02-2022-recommendations-announced-for-influenza-vaccine-compositionfor-the-2022-2023-northern-hemisphere-influenza-season Flu activity peak months in the U.S. from the 1982-1983 through 2019-2020 flu seasons



FLU SEASON TIMING



www.cdc.gov/flu/weekly/index.htm

Don't forget to submit your questions in the Questions and Answers box!

2022-23 SEASONAL INFLUENZA VACCINE RECOMMENDATIONS

ACIP RECOMMENDATIONS FLU VACCINE TIMING INFLUENZA VACCINE PRODUCTS



INFLUENZA RECOMMENDATIONS

<u>Prevention and Control of</u> <u>Seasonal Influenza with Vaccines:</u> <u>Recommendations of the Advisory</u> <u>Committee on Immunization</u> <u>Practices — United States, 2022–</u> <u>23 Influenza Season | MMVVR</u> (cdc.gov)

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season

Lisa A. Grohskopf, MD¹; Lenee H. Blanton, MPH¹; Jill M. Ferdinands, PhD¹; Jessie R. Chung, MPH¹; Karen R. Broder, MD²; H. Keipp Talbot, MD³; Rebecca L. Morgan, PhD⁴; Alicia M. Fry, MD¹

¹Influenza Division, National Center for Immunization and Respiratory Diseases, CDC; ²Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, CDC; ³Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee; ⁴Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

Summary

This report updates the 2021–22 recommendations of the Advisory Committee on Immunization Practices (ACIP) concerning the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2021;70[No. RR-5]:1–24). Routine annual influenza vaccination is recommended for all persons aged ≥ 6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. With the exception of vaccination for adults aged ≥ 65 years, ACIP makes no preferential recommendation for a specific vaccine when more than one licensed, recommended, and age-appropriate vaccine is available. All seasonal influenza vaccines expected to be available in the United States for the 2022–23 season are quadrivalent, containing hemagglutinin (HA) derived from one influenza A(H1N1)pdm09 virus, one influenza A(H3N2) virus, one influenza B/Victoria lineage virus, and one influenza B/Yamagata lineage virus. Inactivated influenza vaccines (IIV4s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Trivalent influenza vaccines are no longer available, but data that involve these vaccines are included for reference.

Influenza vaccines might be available as early as July or August, but for most persons who need only 1 dose of influenza vaccine for the season, vaccination should ideally be offered during September or October. However, vaccination should continue after October and throughout the season as long as influenza viruses are circulating and unexpired vaccine is available. For most adults (particularly adults aged \geq 65 years) and for pregnant persons in the first or second trimester, vaccination during July and August should be avoided unless there is concern that vaccination later in the season might not be possible. Certain children aged 6 months through 8 years need 2 doses; these children should receive the first dose as soon as possible after vaccine is available, including during July and August. Vaccination during July and August can be considered for children of any age who need only 1 dose for the season and for pregnant persons who are in the third trimester if vaccine is available during those months.

Updates described in this report reflect discussions during public meetings of ACIP that were held on October 20, 2021; January 12, 2022; February 23, 2022; and June 22, 2022. Primary updates to this report include the following three topics: 1) the composition of 2022-23 U.S. seasonal influenza vaccines; 2) updates to the description of influenza vaccines expected to be available for the 2022-23 season, including one influenza vaccine labeling change that occurred after the publication of the 2021-22 ACIP influenza recommendations; and 3) updates to the recommendations concerning vaccination of adults aged ≥65 years. First, the composition of 2022–23 U.S. influenza vaccines includes updates to the influenza A(H3N2) and influenza B/Victoria lineage components. U.S.-licensed influenza vaccines will contain HA derived from an influenza A/Victoria/2570/2019 (H1N1)pdm09-like virus (for egg-based vaccines) or an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus (for cell culture-based or recombinant vaccines); an influenza A/Darwin/9/2021 (H3N2)-like virus (for egg-based vaccines) or an influenza A/Darwin/6/2021 (H3N2)-like virus (for cell culture-based or recombinant vaccines); an influenza B/Austria/1359417/2021 (Victoria lineage)-like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus. Second, the approved age indication for the cell culture-based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), was changed in October 2021 from ≥2 years to ≥6 months. Third, recommendations for vaccination of adults aged ≥65 years have been modified. ACIP recommends that adults aged \geq 65 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza

Corresponding author: Lisa A. Grohskopf, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC. Telephone: 404-639-2552; Email: lgrohskopf@cdc.gov. vaccine should be used. This report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the



CORE INFLUENZA VACCINE RECOMMENDATION

- Routine annual flu vaccination is recommended for ALL persons aged 6 months and older who do not have contraindications
- With the exception of vaccination for adults 65 years and older, no preferential recommendation is made for one flu vaccine product over another when more than one licensed, recommended, and ageappropriate product is available



TIMING OF FLUVACCINATION

- ACIP recommends that flu vaccination be offered by the end of October
- Children aged 6 months through 8 years who need 2 doses should receive their 1st dose ASAP after vaccine becomes available to allow the 2nd dose to be received ideally by the end of October
 - Minimum interval: 4 weeks
 - If both doses haven't been received by the end of October, still complete the 2-dose series
- Children of any age needing I dose this season, should also ideally be vaccinated by the end of October. Vaccination of these children can occur as soon as vaccine is available, as there is less evidence to suggest waning immunity among children compared with adults
- For non-pregnant adults, influenza vaccination during July and August should be avoided unless there is concern that later vaccination might not be possible




TIMING OF FLUVACCINATION, CONT.

- Pregnant Persons in First or Second Trimester
 - Waiting to vaccinate until September or October is preferable, unless there is concern that later vaccination might not be possible
- Pregnant Persons in Third Trimester
 - Vaccination soon after vaccine becomes available (July/August) can be considered for pregnant persons during the third trimester, as vaccination of pregnant persons has been shown to reduce risk of influenza illness of their infant during the first months of life



TIMING OF FLU VACCINATION, CONT'D.



- Continue to vaccinate as long as flu viruses are circulating, and unexpired vaccine is available
- No recommendation is made for revaccination (i.e., providing a booster dose)
 later in the season for persons who have already
 been fully vaccinated



TYPES OF INFLUENZA VACCINE AVAILABLE IN 2022-23 SEASON

- Main Influenza vaccine types:
 - IIV4=inactivated influenza vaccine, quadrivalent
 - RIV4=recombinant influenza vaccine, quadrivalent
 - LAIV4=live attenuated influenza vaccine, quadrivalent
- Prefixes are used when necessary to refer to some specific IIVs
 - a=adjuvanted inactivated influenza vaccine quadrivalent (allV4)
 - cc=cell culture-based inactivated influenza vaccine quadrivalent (ccllV4)
 - HD=high-dose inactivated influenza vaccine quadrivalent (HD-IIV4)
- Numerals following the letter abbreviations indicate the number of flu strains represented in the vaccine
 - All influenza vaccines available in the U.S. for the 2022-2023 season are expected to be quadrivalent



A LOOK AT IIV4
IIV4
Flu Strains: 2 A, 2 B
Product Type: Egg-based, standard-dose (SD), unadjuvanted
Age Indication: 6 months and older
Route: IM (Intramuscularly)
For persons who are healthy, have any underlying medical conditions, or who are pregnant
DHHS an Department or Health a Human Services



A LOOK AT HD-IIV4 AND allV4

HD-IIV4 (Fluzone [®] High-Dose Quadrivalent)	allV4 (Fluad® Quadrivalent)						
Flu Strains: 2 A, 2 B							
Route: Give intramuscularly (IM)							
Age Indication: 65 years and older							
Has 4x more antigen than SD flu vaccine	Adjuvant (MF59) added to create stronger immune response						

For persons who are healthy or have any underlying medical conditions

A LOOK AT CCIIV4 AND RIV4

ccIIV4 (Flucelvax [®] Quadrivalent)	RIV4 (Flublok [®] Quadrivalent)						
Flu Strains: 2 A, 2 B							
Route: Give intramuscularly (IM)							
Age: 6 months and older	Age: 18 years and older						
Produced in a mammalian cell line	Produced in an insect cell line						
For persons who are healthy, have any underlying							
medical conditions, c	or who are pregnant 20						
MEDHHS Nichigan Department or Health & Human Services							

A LOOK AT LAIV4

LAIV4 (FluMist[®] Quadrivalent)

Flu Strains: 2 A, 2 B

Route: Administered intranasally (IN/NAS)

Age Indication: 2-49 years (healthy, not pregnant)



Do not miss an opportunity to vaccinate, use any age-appropriate flu vaccine that is available!

INFLUENZA VACCINATION FOR PERSONS 65 YEARS AND OLDER

- NEW! ACIP recommends that adults aged 65 years and older preferentially receive any one of the following higher dose or adjuvanted influenza vaccines:
 - Quadrivalent high-dose inactivated influenza vaccine (HD-IIV4),
 - Quadrivalent recombinant influenza vaccine (RIV4), or
 - Quadrivalent adjuvanted inactivated influenza vaccine (allV4)
- If none of these three vaccines are available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be administered



<u>Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory</u> <u>Committee on Immunization Practices — United States, 2022–23 Influenza Season | MMWR (cdc.gov)</u>

2022-23 FLU VACCINE PRESENTATION CHART

- Lists flu vaccine products, brand names, age indications, product presentations
- Multi-dose vials:
 - Afluria: once stopper has been pierced, discard vial after 28 days or 20 needle punctures to the vial, whichever comes first
 - Fluzone: max 10 doses can be withdrawn (even if 0.25 mL doses)
 - Flucelvax: use up until exp. date

 $\frac{www.michigan.gov/flu}{Resources for Health Professionals}$

Seasonal Influenza Vaccines 2022-2023

Use the Correct Product and Presentation Based on the Patient's Age and Status

Vaccine Type ¹	Brand	Presentation	Age Indication ²	
		QUADRIVALENT		
IIV4	Fluarix [®] Quadrivalent (GlaxoSmithKline)	Prefilled 0.5 mL syringe	6 months & older ²	
IIV4	FluLaval [®] Quadrivalent (GlaxoSmithKline)	Prefilled 0.5 mL syringe	6 months & older ²	
		5.0 mL multi-dose vial ⁴	6 through 35 months (0.25 or 0.5 mL)	
IIV4	Fluzone [®] Quadrivalent	5.0 mL multi-dose viai	3 years & older (0.5 mL)	
	(Sanofi Pasteur)	Prefilled 0.5 mL syringe	6 months & older 2	
		0.5 mL single-dose vial	6 months & older -	
IIV4	Afluria [®] Quadrivalent (Seqirus)		6 through 35 months (0.25mL) ²	
		5.0 mL multi-dose vial ^{4,5}	3 years & older (0.5 mL)	
		Prefilled 0.5 mL syringe	3 years & older	
LAIV4	FluMist [*] Quadrivalent (AstraZeneca)	Prefilled 0.2 mL single-use intranasal sprayer	2 through 49 years if healthy and not pregnant persons	
ccIIV4	Flucelvax [®] Quadrivalent	Prefilled 0.5 mL syringe	6 months & older ²	
cciiv4	(Seqirus)	5.0 mL multi-dose vial ⁴	6 months & older (0.5 mL) ²	
RIV4 ⁶	Flublok [®] Quadrivalent (Sanofi Pasteur)	Prefilled 0.5 mL syringe	18 years & older	
HD-IIV4 ⁶	Fluzone [®] High-Dose (Sanofi Pasteur)	Prefilled 0.7 mL syringe ²	65 years & older	
allV4 ⁶	Fluad ^{*3} Quadrivalent (Segirus)	Prefilled 0.5 mL syringe	65 years & older	

Available VFC presentations are in gray boxes.

¹Abbreviations: Inactivated Influenza <u>V</u>accine (IIV4), Adjuvanted (aIIV4), High-Dose (HD-IIV4), <u>Cell Culture-based (cclIV4),</u> <u>Recombinant Influenza V</u>accine (RIV4); <u>Live A</u>ttenuated Influenza <u>V</u>accine (LAIV4). Numbers indicate number of flu virus antigens.

²Dose volume for standard-dose IIV is based on age and flu vaccine product. For 3 years and older, dose volume is 0.5 mL regardless of flu vaccine product (exception: Fluzone High-Dose the correct volume is 0.7 mL). Dose volume for IIV4 vaccines for children aged 6-35 months: 0.25 mL per dose of Afluria; 0.5 mL per dose for Fluarix and FluLaval; either 0.25 mL per dose or 0.5 mL per dose of Fluzone. No preference is expressed for either Fluzone dose volume for this age group. Dose volume of cclIV4 vaccine for children aged 6 months and older: 0.5 mL per dose of FluceIvax. See "2022-23 Seasonal Influenza Vaccine Dose Volumes for Children" at www.michigan.gov/flu/resources/resources-for-health-professionals.

³Fluad includes the adjuvant MF59C.1.

⁴Per the package inserts, for Afluria Quadrivalent, "once the stopper of the multi-dose vial has been pierced the vial must be discarded within 28 days. The number of needle punctures should not exceed 20 per multi-dose vial." For Fluzone Quadrivalent, "a maximum of 10 doses can be withdrawn from the multi-dose vial," even if drawing out 0.25 mL doses. A Flucelvax Quadrivalent multi-dose vial may be used up until the expiration date.

⁵Afluria is approved by the Food and Drug Administration for intramuscular administration with a PharmaJet[®] Stratis[®] Needle-Free Injection System for persons aged 18 through 64 years.

⁶ACIP recommends that adults aged 65 years and older preferentially receive any one of the following: HD-IIV4, RIV4, or aIIV4. If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be administered.

Use this chart to help prevent errors. Highlight the flu vaccine(s) you have in your storage unit and know the age indications. Ensure you give the correct vaccine at the correct dose volume to the correct person based on age. For 2-dose recommendations, see "Who Needs 2 Doses of 2022-23 Seasonal Influenza Vaccine?" at <u>www.michigan.gov/flu/resources/resources-forhealth-professionals</u>. Refer to "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP—U.S., 2022-23 Influenza Season," MMWR Recomm Rep 2022;-71(1); 1-28, located at <u>www.cdc.gov/vaccines/hcp/acip-recs/vaccspecific/flu.html</u>. For additional information regarding flu and flu vaccination, refer to <u>www.michigan.gov/flu</u>, <u>www.cdc.gov/vaccines</u>, or <u>www.cdc.gov/mmwr</u>.

Michigan Department of Health and Human Services — Division of Immunization Rev. September 6, 2022



FLU VACCINE GUIDANCE FOR USE IN CHILDREN

PEDIATRIC DOSE VOLUMES NUMBER OF DOSES NEEDED IN 2022-23 SEASON



INFLUENZA VACCINE DOSE VOLUMES

- Five IIV4 products are approved for persons 6 months and older
- For 6-35 months, dose volume depends on the flu vaccine product that is administered

For children aged 3 years and older, dose volume for SD-IIV is **0.5 mL** regardless of the flu vaccine product being administered

If You're Using This Vaccine	Dose Volume for Ages 6-35 Months
Afluria (Seqirus)	0.25 mL per dose
Fluarix, FluLaval (GSK), or Flucelvax (Sequirus),	0.5 mL per dose
Fluzone (Sanofi Pasteur)	0.25 mL OR 0.5 mL per dose *No preference is expressed for either dose volume



INFLUENZA VACCINE DOSE VOLUMES, CONT'D.

For IIV4, the needed volume for a child 6-35 months may be administered from a manufacturer supplied prefilled syringe, a single-dose vial, or a multi-dose vial

Further Guidance for Fluzone Quadrivalent:

- Single-dose 0.5 mL vials of Fluzone Quadrivalent should be used for only 1 dose. If 0.25 mL is used from a Fluzone Quadrivalent 0.5 mL single-dose vial, then the 0.25 mL remaining in the single-dose vial must be discarded
- Vaccine Administration Error Case Study:
- A 6-month-old was inadvertently given a 0.25 mL dose of FluLaval (or Fluarix or Flucelvax) rather than the recommended 0.5 mL dose. What do you do?
 - If you recognize the error that same day, give a second 0.25 mL dose of the product that was used. This equals a full dose for this child. If the error is not discovered until the next day, the 6-month-old needs to be revaccinated with a full dose of IIV4 ASAP (this will be the 1st dose of this infant's 2-dose series)



2022-23 FLU VACCINE DOSE VOLUMES FOR CHILDREN

- Prevent flu vaccine administration errors in children
- Covers pediatric dosage by vaccine, how to correct common vaccine administration errors

<u>www.michigan.gov/flu</u> \rightarrow Resources \rightarrow Resources for Health Professionals

2022-23 Seasonal Influenza Vaccine Dose Volumes for Children

Everyone aged 6 months and older should receive flu vaccine every year.

Flu vaccine dose volume is based on the person's **age and the flu vaccine product** that is used.¹ A study in 2016 found that flu vaccine was most frequently involved in reported vaccine errors (20%) and was the most common type of vaccine implicated in age-related vaccine errors.² It is important to prevent flu vaccine administration errors to ensure children are adequately protected against flu.

For children aged **6 through 35 months**, flu vaccine dose volume is **dependent on the product that is administered**. There are multiple licensed inactivated influenza vaccines, quadrivalent (IIV4) available for children aged 6 through 35 months: Afluria^{*} Quadrivalent, FluLaval^{*} Quadrivalent, Fluarix^{*} Quadrivalent, and Fluzone^{*} Quadrivalent. The cell cultured-based inactivated influenza vaccine (ccIIV4) is available for persons aged 6 months and older (Flucelvax^{*} Quadrivalent).

If You're Using This Vaccine (IIV4) ¹	Dose Volume for Ages 6-35 Months				
Afluria (Seqirus)	0.25 mL per dose				
Fluarix or FluLaval (GSK)	0.5 mL per dose				
Fluzone (Sanofi Pasteur)	0.25 mL OR 0.5 mL per dose *No preference is expressed for either dose volume.				
If You're Using This Vaccine (ccIIV4) ¹	Dose Volume for Ages 6-35 Months				
Flucelvax (Seqirus)	0.5mL per dose				

Refer to the Flu Vaccine Presentation Chart (see footnote 1) for available presentations of each of these vaccines.

For children aged 3 years and older, dose volume for standard-dose IIV is 0.5 mL regardless of the flu vaccine product being administered.

If 2 doses of 2022-23 flu vaccine are needed³, the same vaccine product **does not** need to be used for both doses. Use any age-appropriate flu vaccine that is available that day, ensuring you use the correct dose volume for the product you are administering.

Don't miss an opportunity to vaccinate! Dose volume is based on the child's age on the day of vaccine administration. For example:

- If a child is aged 2 years and 11 months for dose 1, use the above table to determine dose volume based on the IIV/ccIIV product used.
- When the child returns 4 weeks later for dose 2 and is now aged 3 years, the dose volume is 0.5 mL regardless of the IIV/ccIIV product used.

For IIV, the needed volume for a child aged 6 through 35 months may be administered from a prefilled syringe containing the appropriate volume (as supplied by the manufacturer), a single-dose vial, or a multi-dose vial.

Further Guidance on Fluzone Quadrivalent:

- NOTE: Fluzone Quadrivalent is approved for children aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose.
- The 0.25-mL prefilled syringe of Fluzone Quadrivalent is not available for the 2022–23 season. If a
 prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be
 0.5 mL per dose.

Rev. August 30, 2022 Page 1 of 2






2-DOSE RECOMMENDATION: 6 MONTHS-8 YEARS

- # of doses needed is based on child's age at time of 1st dose of 2022-23 flu vaccine and # of doses of flu vaccine received in previous seasons
- How many seasonal (i.e., trivalent, quadrivalent) flu vaccines received before 7/1/2022
 - If 2 or more doses: give 1 dose this season
 - If only I dose or has NEVER received flu vaccine: give 2 doses this season (separate by 4 weeks)
- 2 doses do not need to be from the same season or consecutive seasons, need to be spaced at least 4 weeks apart
- Give 1st dose as soon as possible after vaccine is available, 2nd dose by end of October
- If the child turns 9 years between dose 1 and dose 2, still give dose 2

MCIR is programmed for 2-dose assessment. Make sure to use MCIR! <u>www.michigan.gov/flu</u> \rightarrow Resources \rightarrow Resources for Health Professionals

Who Needs 2 Doses of 2022-23 Seasonal Influenza Vaccine?

2022-23 Pediatric 2-Dose Algorithm for Children Aged 6 Months through 8 Years





*Doses do not need to have been administered in the same season or consecutive seasons

**Minimum interval between the 2 doses is 4 weeks

Points to consider for the 2022-23 Influenza Season

- All persons aged 6 months and older without contraindications need at least 1 dose of 2022-23 flu vaccine
- Determination of the number of doses needed is based on the child's age at the time of the 1st dose of 2022-23 flu vaccine and the number of doses of flu vaccine received in previous flu seasons
- Children aged 6 months through 8 years need 2 doses of flu vaccine during their 1st season of vaccination
- Children aged 6 months through 8 years who received 2 or more total doses of any trivalent or quadrivalent flu vaccine (e.g., IIV3, IIV4, LAIV3, LAIV4, ccIIV3, ccIIV4) a minimum of 4 weeks apart before July 1, 2022, only need 1 dose of 2022-23 flu vaccine
- If a child has not received at least 2 trivalent or quadrivalent flu vaccines before July 1, 2022, or their flu
 vaccination history is unknown, give 2 doses of 2022-23 flu vaccine separated by 4 weeks
 - Give the 1st dose as soon as possible after vaccine becomes available to allow the 2nd dose to be received by the end of October
 - The same vaccine product does not need to be used for both doses; use any age-appropriate flu vaccine that is available that day (and ensure you use the correct dose volume, see box below)
 - Two doses are recommended even if the child turns age 9 years between receipt of dose 1 and dose 2
- When assessing a child's flu vaccine history to determine if 1 or 2 doses are needed, only review flu vaccine doses given prior to July 1, 2022 (i.e., do not include doses received during the 2022-23 flu season)
- Acronyms: <u>Inactivated Influenza Vaccine</u>, trivalent (IIV3) and quadrivalent (IIV4); <u>cell culture based IIV</u>, trivalent (ccIIV3) and quadrivalent (ccIIV4); <u>Live Attenuated Influenza Vaccine</u>, trivalent (LAIV3) and quadrivalent (LAIV4); **NOTE**: not all these presentations¹ are available in 2022-23

Remember dose volume for standard-dose injectable IIV is based on age and flu vaccine product²:
Dose volume for children aged 3 years and older is 0.5 mL regardless of flu vaccine product
Dose volume of IIV4 vaccines for children aged 6-35 months: 0.25 mL per dose of Afluria^{*} Quadrivalent; 0.5 mL per dose for Fluarix^{*} Quadrivalent, and FluLaval^{*} Quadrivalent; either 0.25 mL per dose or 0.5 mL per dose of Fluzone^{*} Quadrivalent. No preference is expressed for either Fluzone dose volume for this age group.
Dose volume of ccIIV4 vaccine for children aged 6 months and older: 0.5 mL per dose of Flucelvax^{*} Quadrivalent.

¹For more information on available flu vaccine presentations, refer to "Seasonal Influenza Vaccines 2022-2023" at <u>www.michigan.gov/flu/resources/resources-for-health-professionals</u>.

²For more information on pediatric flu vaccine dose volume, refer to "2022-23 Seasonal Influenza Vaccine Dose Volumes for Children" at <u>www.michigan.gov/flu/resources/resources-for-health-professionals</u>.

Refer to "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP – U.S., 2022-23 Influenza Season," MMWR Recomm Rep 2022; 71(1):1-28, located at <u>https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html</u>. For more information regarding flu vaccination, refer to <u>www.michigan.gov/flu</u>, <u>www.cdc.gov/vaccines</u>, or <u>www.cdc.gov/mmwr</u>.


Michigan Department of Health and Human Services - Division of Immunization Rev. August 29, 2022

FLUVACCINE & PREGNANCY



PREGNANCY FLU VACCINE RECOMMENDATION

- Pregnant and postpartum persons have been observed to be at higher risk for severe illness and complications from flu, particularly during 2nd and 3rd trimesters
- Flu vaccination during pregnancy lowers risk of flu hospitalization in pregnant persons by average 40%, in babies <6 months old by average 72%
- ACIP and ACOG recommend that:
 - All persons who are pregnant or who might be pregnant or postpartum during the flu season receive flu vaccine
 - Any licensed, recommended, and age-appropriate IIV or RIV4 may be used (LAIV4 should not be used during pregnancy)
 - Administer at any time during pregnancy, before and during the flu season



Recommendations

immunization for themselves and their fetuses and The American College of Obstetricians and Gynecologists advocate for the benefits of passive immunity from maternal immunization for their newborns. (ACOG) makes the following recommendations: · Obstetrician-gynecologists are encouraged to stock · The Centers for Disease Control and Prevention's and administer the influenza vaccine to their preg-

- www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Influenza-Vaccination-During-Pregnancy
- https://www.cdc.gov/media/releases/2019/p1008-vaccination-moms-babies-unprotected.html
- www.cdc.gov/flu/highrisk/pregnant.htm Pregnant & Flu Vaccine Studies 3.

Don't forget to submit your questions in the Questions and Answers box!

INFLUENZA VACCINATION ADMINISTRATION

SCREENING FOR VACCINATION EGG ALLERGY VACCINE ADMINISTRATION COADMINISTRATION



SCREENING FOR CONTRAINDICATIONS AND PRECAUTIONS

Information for Healthcare Professionals about the Screening Checklist for Contraindications to Inactivated Injectable Influenza Vaccination (IIV4 or RIV4)

Are you interested in knowing why we included a certain question on the screening checklist? If so, read the

- Screen for contraindications and precautions every time vaccines are indicated
- Use a standardized form
- Help prevent vaccine errors
- Follow only valid contraindications and precautions
- Document any permanent or temporary contraindications/precautions in the chart/EMR

		sult the "Note" below.						
Screening Checklist	have reactions to thimerosal when it is used in vaccines. the package insert at www.immunize.org/fda for a list of ccine components (i.e., excipients and culture media) used production of the vaccine, or go to www.fda.gov/vaccines-							
for Contraindications								
to Inactivated Injectable Infl	uenza Vaccination	biologics, 2021-20 Information for He	althca	are F		sionals about the Screening Checklist uated Intranasal Influenza Vaccinatior		
						d a certain question on the screening checklist? If so, read ti en more, consult the "Note" below. In this document, IIV re		
influenza vaccination today. If you answer you (or your child) should not be vaccinate	Screening Checklist	PATIENT NAME				 Does the person to be vaccinated have a) an open channel between t cerebrospinal fluid (CSF) and the mouth, throat, nose or ear or any of 		
If a question is not clear, please ask your h		DATE OF BIRTH//				cranial CSF leak, or b) a cochlear implant, or c) an immunocomprom condition due to any cause (e.g., medication, congenital or acquired immunodeficiency, HIV infection, or a missing or non-functioning so		
	to Live Attenuated Intran	asal Influenza Vaco	cinat	tior	ı	[e.g. caused by sickle-cell disease])? People with these conditions should not be given LAIV4. Instead, the should be given an IIV4 or RIV4 appropriate for their age.		
1. Is the person to be vaccinated sick toda						8. Is the person to be vaccinated currently taking influenza antiviral		
 2. Does the person to be vaccinated have of the vaccine? 3. Has the person to be vaccinated ever have be vac	reason we should not give you or your chil (LAIV4, FluMist) today. If you answer "yes should not be vaccinated. It just means ad	s: The following questions will help us dete d live attenuated intranasal influenza vacci " to any question, it does not necessarily me ditional questions must be asked. If a ques	ine, quad ean you (e	rivalen or your	t child)	medication, or have they taken any with the past 3 weeks? Receipt of certain influenza antivital could reduce LAIM vaccine effectiveness; therefore, providers should defer vaccination with LMU people who took anamativity or oselamitivit with 48 hours, peramitivit S days, or halowavir within 17 days. Patients should also be advised to use of these antivitains for 1 days after vaccination, if fasible. Any II		
to influenza vaccine in the past?	please ask your healthcare provider to exp	lain it.	yes	no	don't	RIV4 may be administered without regard to antiviral use.		
4. Has the person to be vaccinated ever ha	1. Is the person to be vaccinated sick today?				know	years who is receiving aspirin therapy or aspirin-containing therapy? Because of the theoretical risk of Reye's syndrome, children age 6 mo		
	 Does the person to be vaccinated have an allergy to an 	ingredient of the influenza vaccine?				through 17 years on aspirin therapy should not be given LAIV4. Inste- they should be vaccinated with any IIV4 or RIV4.		
	3. Has the person to be vaccinated ever had a serious reaction to influenza vaccine in the past?					 Is the person to be vaccinated pregnant or could they become pregn within the next month? 		
FORM COMPLETED BY	4. Is the person to be vaccinated younger than age 2 years or older than age 49 years?					Pregnant people or those planning to become pregnant within a mo should not be given LAIV4. All pregnant people should, however, be		
	 Does the person to be vaccinated have a long-term health problem with heart disease, lung disease (including asthma), kidner disease, neurologic disease, liver disease, or metabolic disease (e.g., diabetes); 					vacinated with IIV4 or RIV4. Pregnancy testing is not necessary before administering LAIV4. 11. Has the person to be vaccinated ever had Guillain-Barré syndrome? Propole who are not at high risk for severe influenza complications as		
	 6. If the person to be vaccinated is a child age 2 through 4 years, in the past 12 months, has a healthcare provider told you the child had wheezing or asthma? 7. Does the person to be vaccinated have a) an opten channel between the cerebrospinal fluid (CSF) and the mouth, throat, nose or ear or any other channel between the cerebrospinal fluid (CSF) and the mouth, throat, nose or ear or any other cranial CSF leak, or b) a cochlear implant, or 0 an immunocompromising condition due to any cause (e.g., medication, congenital or acquired immunodeficiency, HIV infection, or a missing or non-functioning spleen [e.g., caused by sickle cell disease])? 8. Is the person to be vaccinated currently taking influenza antiviral medications, or have they taken any within the past 3 weeks? 					are known to have not a might that to be serve immedia a compactation are known to have developed GES within 6 weeks after receivin influenza vaccination should generally not be vaccinated. As a clinicians might consider using influenza antiviral chemoprop these people. However, the benefits of influenza vaccination		
						outweigh the possible risks for certain people who have a histoi within 6 weeks after receipt of influenza actions and who are at risk for severe complications from influenza. 12. Does the person to be vaccinated live with or expect to have close with a person whose immuse system is severely compromised an must be in potective isolation (e.g., an isolation room of a bone to protective isolation (e.g., an isolation room of a bone)		
						transplant unit)? An IIV4 or RIV4 is preferred for people who anticipate close cont severely immunosuppressed person during periods in which the i suppressed person requires care in protective isolation (e.g., in a		
	9. Is the person to be vaccinated a child or teen age 6 months through 17 years and receiving aspirin- or salicylate-containing medicine?					ized patient-care area with a positive airflow relative to the corridor, efficiency particulate air filtration, and frequent air changes). Any IIV RIV4, or LAIV4 may be used in people who have close contact with pe having lesser degrees of immunosuppression.		
	10. Is the person to be vaccinated pregnant or could they b	become pregnant within the next month?				13. Has the person to be vaccinated received any other vaccinations in t		
immunization action coelition	11. Has the person to be vaccinated ever had Guillain-Barr					4 weeks? People who were previously given an injectable live virus vaccine (MMR, MMRV, varicella, yellow fever) should wait at least 28 days		
Saint Paul, Minnesota - 651-647-9009 - www.immunize	12. Does the person to be vaccinated live with or expect to have close contact with a person whose immune system is severely compromised and who must be in protective isolation (e.g., an isolation room of a bone marrow transplant unit)?					receiving LAIV4 (30 days for yellow fever). LAIV4 can be given on th same days as other live vaccines. There is no reason to defer givin LAIV4 if people were vaccinated with an inactivated vaccine (includ COVID-19 vaccine), or if they have recently received blood or other		
	13. Has the person to be vaccinated received any other vac	cinations in the past 4 weeks?				antibody-containing blood products (e.g., IG).		
	FORM COMPLETED BY			DATE		FOR THE PUBLIC WWW.vaccineinformation.org www.immunize.org/catg.d/p4067.pdf • Item #P406		
	FORM REVIEWED BY DATE							



CONTRAINDICATIONS TO FLU VACCINE

- IIV4/LAIV4: History of severe allergic reaction to any component of the vaccine* or to a previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV)
- ccIIV4: History of severe allergic reaction to a previous dose of any ccIIV or any component of ccIIV4
- RIV4: History of severe allergic reaction to a previous dose of any RIV or any component of RIV4
- LAIV4:
 - Concomitant aspirin- or salicylate-containing therapy (children and adolescents)
 - Children aged 2-4 years with a history of asthma or documented wheezing episode in the past 12 months
 - Immunocompromised due to any cause, including immunosuppression caused by medications, congenital or acquired immunodeficiency states, HIV infection, anatomic asplenia, or functional asplenia (e.g., sickle cell anemia)
 - Close contacts/caregivers of severely immunosuppressed persons who require a protected environment
 - Pregnancy
 - Active communication between CSF and oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak
 - Cochlear implants
 - Receipt of flu antivirals within previous 48 hours (oseltamivir, zanamivir), previous 5 days (peramivir), previous 17 days (baloxavir)



*However, ACIP recommends that persons with history of egg allergy may receive any flu vaccine otherwise appropriate for their age/health status

PRECAUTIONS TO FLU VACCINE

- IIV4/ccIIV4/RIV4/LAIV4: Moderate or severe acute illness with or without fever and history of Guillain-Barré syndrome within 6 weeks of previous flu vaccine
- ccIIV4: History of severe allergic reaction to a previous dose of any other influenza vaccine (i.e., any egg-based IIV, RIV, or LAIV)*
- RIV4: History of severe allergic reaction to a previous dose of any other influenza vaccine (i.e., any egg-based IIV, ccIIV, or LAIV)*
- LAIV4:
 - Asthma in persons aged 5 years and older
 - Other underlying medical conditions that might predispose to complications after wild-type influenza infection (e.g., chronic pulmonary, cardiovascular [excluding isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes mellitus])

*If administered, vaccination should occur in a medical setting and should be supervised by a health care provider who can recognize and manage severe allergic reactions. Providers can consider consultation with an allergist in such cases, to assist in identification of the component responsible for the allergic reaction.



Quick Looks at Using IIV4, ccIIV4, RIV4, and LAIV4

	: :::elent);					
it spines (Q'		Vaccina (Quadrivalent): LAIVA	Quick Look at Recombinent			
t Inactivated Influenza Vaccines (-	RIV4	Influenza Vaccine (Quadrivalent):	Quadrivalent): c <u>ok a</u> t <u>C</u> ell <u>C</u> ulture-basec (Quadrivalent): c	d <u>I</u> nactivated <u>I</u> nfluenza <u>V</u> accine ccIIV4, 2022-23
Quick Look at Inactivated Influenza Vaccines (Quick Look at Inactivated Influenza Vaccines (Quick High-Dose IIV4 (HD-IIV4), and Adjuvanted IIV4 (More at the second of the	Are healthy Are not pregnant Vaccination is recommended to be offered by the end of October and continued throughout the flu season until vaccine expires (see below for further timing considerations) Kev Points	 Vaccine Administration1 Administer intranasal 0.2 mL Spray 0.1 mL into each nostril as indi dose-divider clip on sprayer Use 0.2 mL dose for all ages 2 througi LAIV4 can be given with other vaccines at visit – do not miss an opportunity If LAIV4 is not given on the same day as o vaccines (MMR, Var, MMRV), separate by For more on LAIV4 administration, refer tr "Administering Influenza Vaccines" at the same day as or the sa	Windcatons for Use and Schedule Use RIV4 (Flublok® Quadrivalent) for persons aged 18 years and older Vaccination is recommended to be offered by the end of October and Continued throughout the flu season unll vaccine expires (see below for further timing considerations) Key Points With the	Vaccine Administration: • Administer RIV4 intramuscular (IM) in the deltoid of the arm (preferred) or anterolateral thigh using a 1- to 1.5-inch needle • Must administer vaccine IM, if given by another rout should repeat dose as soon as possible • Can be given with other vaccines at the arm of on on the merim with other vaccines at the arm	recommended for all er, including all healthy ile trivalent) for persons aged d to be offered by the end of oughout the flu season until	 CIIV4, 2022-23 Vaccine Administration1 Administer collV4 intramuscular (IM) in the deltoid of the arm (preferred) or the anterolateral thigh Children: 1-inch needle Adolescents/adults: 1 to 1.5-inch needle Must administer vaccine IM, if given by another route; should repeat dose as soon as possible Can be given with other vaccines at the same visit – do not miss an opportunity Use separate sites, space at least 1-inch apart
 HD-IN4, and an overvelowing and older and older and older vaccinations is recommended to be offered by the ensount of the season until October and continued throughout the flue season until October and Content of the season of adults 65 years and older there is no preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another on preference for any flue vaccine product over another over another on preference for any flue vaccine product over another over a	 Not the excination or duration of the second of the second	www.michipan.gov/flu/resources/resource health-orofessionals Storage and Handling • Store in the refrigerator at 36°F to 46°F • Pharmaceutical-grade (purpose-built) u preferred for vaccine storage • Do not freeze; keep in original box with from light • Do not use expired vaccine • LAIV4 expiration dates differ from oth expiration dates	Ensure vaccination occurs with an age- appropriate product and dose volume Aduits 65 years and older should preferentially receive either HD-IIV4, RIV4, or all/V4 If none of these three vaccines are available, then any other age-appropriate influenza vaccine should be used NFLUENZA DOSE VOLUME IS BASED ON AGE AND FLU VACCINE PROPULA RIV4 dosage for persons and tage.	Storage and Handling Storage and Handling Storage and Handling Store in the refrigreator at 36°F to 46°F (2°C to 8°C) Pharmaceutical-grade (purpose-built) units are preferred for vaccine storage Do not freeze; keep in original box with lid on/protect from light Store different flu vaccine formulations apart and label with age indications	ults 65 years and older, there u vaccine product over another curs with an age-appropriate	 Use separate sites, space at least 1-inch apart Store in the refrigerator at 36°F to 46°F (2°C to 8°C) Pharmaceutical-grade (purpose-built) units are preferred for vaccine storage Do not freeze; keep in original box with lid on/protect from light Store different IIV formulations apart and label with age indications Do not use expirate vaccine Multi-dose vial (MDV) – Flucelvax MDV may be used up until the expiration date, between uses return the MDV to recommended storage conditions
	 INFORMATION ON WHICH CHLIDREN AGED 6 MONTHS THROUGH 8 YEA Determination of the number of doses needed is based on 1 previous seasons and the age at the time of the first dose of Children aged 6 months through 8 years who received 2 or vaccine (i.e., II/3) II/4, LAIV3, LAIV4, ccIIV3, ccIIV4) at lead dose of 2022-23 flu vaccine If a child has not received at least 2 trivalent or quadrivalent 2022, give 2 doses of 2022-23 flu vaccine separated by 4 w Give the 1st dose as soon as possible after vaccine bed available) to allow the 2st dose to be received by the end of Octol Both doses should be administered even if the child tur Refer to "Who Needs 2 Doses of 2022-23 Seasonal Influent www.michigan.gov/flu/resources/resources/ro-thealth-orofe CONTRAINDICATIONS (PERSONS WHO SHOLD NOT RECEIVE LAIV4) Severe allergic reaction (e.g., anaphylaxis) after a previous RIV, or LAIV) or one of its components 	ARS NEED 2 DOSES OF FLU VACCINE: If the number of doses of flu vaccine received of 2022-23 flu vaccine rmore total doses of any trivalent or quadriv ast 4 weeks apart before July 1, 2022, only it flu vaccines at least 4 weeks apart before weeks comes available (including July and Augus nd of October ber, still complete the 2-dose series rms 9 years old between dose 1 and dose traz Vaccine?" at essionals it cose of flu vaccine (i.e., any egg-base ldren and adolescents nosis of asthma or whose parents or o	ONTRAINDICATIONS (PERSONS WHO SHOULD NOT RECEIVE RIV4): Severe allergic reaction (e.g., anaphylaxis) to a previous dose of tecAUTIONS (IN CERTAIN CIRCUMSTANCES, PERSONS MAY RECEIVE RIV4). Moderate or severe acute illness with or without fever History of Guillain-Barré syndrome (GBS) within 6 weeks of prev History of a vere allergic reaction to a previous dose of any oth or LAIV) a severe allergic reaction to a previous dose of any oth ecognition and management of severe allergic conditions is a second tiministered, should occur in a medical setting in which a h recognition and management of severe allergic conditions is a HER POINTS TO CONSIDER: Carination is recommended to be offered by the end of October a For most adults (particularly adults aged 65 years and older) an second trimester: Vaccination during July and August should be vaccination later in the season might not be possible	er dose of any RIV or any component of RIV4 f4): tious flu vaccination ter flu vaccine (i.e., any egg-based IIV, ccIIV, b, traitable traits care provider with experience in the set of the	Ifflu/resources/resources-for-health-profe CHILDREN AGED 6 MONTHS THROUGH 8 YE/ e number of doses needed is based on and the age at the time of the first dose of onths through 8 years who received 2 or IIV4, LAIV3, LAIV4, ccIIV3, ccIIV4) at lea I vaccine ceived at least 2 trivalent or quadrivalen of 2022-23 flu vaccine separated by 4 v se as soon as possible after vaccine ber dose to be received by the end of Octo ave not been received by the end of Octo cine product does not need to be used fru vaccine	JUCT: LL per dose I Influenza Vaccine Dose Volumes for Children" at assionals ARS NEED 2 DOSES OF FLU VACCINE: the number of doses of flu vaccine received in of 2022-23 flu vaccine "more total doses of any trivalent or quadrivalent flu ast 4 weeks apart before July 1, 2022, only need 1 Int flu vaccines at least 4 weeks apart before July 1, weeks comes available (including July and August if available) ber, ensure at least 4 weeks in between doses
 Dose volume time; a single-dose where 6 through For IIV4, the needed volume time; a single-dose where 6 through supplied by the manufacturer, a single-dose where 6 through supplied by the manufacturer is recommended for children 6 through Fluzone Quadrivalent is recommended by syngles are not available dose, however, the 0.25-mL prefilled syringes are not available. 	report that a health care provider has told them during the p or asthma or whose medical record indicates a wheezing ep months		22		ds 2 Doses of 2022-23 Seasonal Influer /flu/resources/resources-for-health-profe	



 $\underline{www.michigan.gov/flu} \rightarrow Resources \rightarrow Resources for Health Professionals}$ $\underline{www.michigan.gov/VaccineQuickLooks}$

FLU VACCINATION FOR PERSONS WITH EGG ALLERGY

- History of egg allergy and only hives after exposure to egg should receive flu vaccine
 - Use any licensed, recommended vaccine (i.e., any IIV4, RIV4, or LAIV4) otherwise appropriate for age/health status
- History of egg allergy and symptoms other than hives (e.g., angioedema or swelling, respiratory distress, lightheadedness, or recurrent vomiting) or required epinephrine/another emergency medical intervention:
 - Can receive any licensed, recommended vaccine (i.e., any IIV4, RIV4, LAIV4) otherwise appropriate for age/health status
 - If a vaccine other than ccIIV4 or RIV4 is used, administer it in an inpatient or outpatient medical setting
 - Supervised by health care provider able to recognize and manage severe allergic reactions



FLU VACCINE & EGG ALLERGY, CONT'D.

- For persons who report egg allergy, it is not recommended to administer divided doses of flu vaccine or to do skin testing with the vaccine before administration
- No post-vaccination observation period is recommended specifically for egg-allergic persons
- Reminder: Screen and review vaccine specific contraindications and precautions

2022-23 Influenza Vaccination for Persons Who Report Egg Allergy

For the 2022-23 influenza season, the Advisory Committee on Immunization Practices (ACIP) recommends the following:

- 1. Persons with a history of egg allergy who have experienced **only hives** after exposure to egg should receive influenza vaccine
 - Use any licensed, recommended influenza vaccine (i.e., any IIV4, RIV4, or LAIV4) that is otherwise appropriate for the person's age and health status
- 2. Persons who report having a reaction to egg involving symptoms **other than hives** (e.g., angioedema or swelling, respiratory distress, lightheadedness, or recurrent vomiting) or who required epinephrine or another emergency medical intervention:
 - Can receive any licensed, recommended influenza vaccine (i.e., any IIV4, RIV4, LAIV4) that is otherwise appropriate for their age and health status
 - If a vaccine other than ccIIV4 or RIV4 is used, it should be administered in an inpatient or outpatient medical setting
 - Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic reactions

Remember:

It is important to screen and review the contraindications and precautions for any vaccine. With flu vaccine it is important to know the type of flu vaccine being administered to assess for vaccine specific contraindications and precautions.

 For further information on contraindications and precautions review the Quick Looks for Influenza Vaccines (IIV4, LAIV4, ccIIV4, and RIV4) at: www.michigan.gov/vaccinequicklooks

"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the ACIP—U.S., 2022-23 Influenza Season," MMWR Recomm Rep 2022; 71(1);1-28, located at <u>www.cdc.gov/vaccines/hcp/acip-recs/index.html</u>. For further information regarding flu vaccination, refer to <u>www.michigan.gov/flu</u>, <u>www.cdc.gov/vaccines</u>, or <u>www.cdc.gov/mmwr</u>.

Page 1 of 2

Michigan Department of Health and Human Services — Division of Immunization



Rev. September 6, 2022

FLU VACCINE ADMINISTRATION

- Covers intramuscular (IM) and intranasal (IN/NAS) administration techniques
- Do skills check-offs for staff in your office


<u>www.michigan.gov/flu</u> \rightarrow Resources \rightarrow Resources for Health Professionals

Administering Influenza Vaccines: Intramuscular and Intranasal

Intramuscular (IM) Injection

Inactivated Influenza Vaccines (aIIV4, HD-IIV4, IIV4, ccIIV4, RIV4)

- Use a needle long enough to reach deep into the muscle. For infants 6 months and older, use a 1" needle. For adolescents and adults, a 1-1 ½" needle should be used.¹
- 2. Choose the appropriate site. With your non-dominant hand, spread the skin taut between the thumb and forefinger, isolating the muscle.
- With your dominant hand, insert the needle at a 90° angle to the skin with a quick thrust.
- Push down on the plunger and inject the entire contents of the syringe. There is no need to aspirate.



- Remove the needle or activate the retraction, if using a retractable safety needle/syringe, then apply light pressure to the injection site for several seconds with a dry cotton ball or gauze pad.
- 6. Cover the injection site with a bandage.
- 7. Put the used needle and syringe in a sharps container.

Intranasal (IN/NAS) Administration

Live Attenuated Influenza Vaccine (LAIV4)

- 1. FluMist® (LAIV4) is for intranasal administration only. Do not inject!
- 2. Remove the rubber tip protector. Do not remove the dose-divider clip at the other end of the sprayer.
- With the patient in an upright position, place the tip just inside the nostril to ensure LAIV4 is delivered into the nose. The patient should breathe normally.



- With a single motion, depress the plunger as rapidly as possible until the dose-divider clip prevents you from going further. Remove from nostril.
- 5. Pinch and remove the dose-divider clip from the plunger.



- Place the tip just inside the other nostril, and with a single motion, depress plunger as rapidly as possible to deliver the remaining vaccine (if the person sneezes after administration, the dose can be counted as valid).
- 7. Put the applicator in a sharps container.

¹ Use professional judgment when determining needle size and injection site. Visit: <u>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</u>. For more information regarding flu and flu vaccination, refer to <u>www.michigan.gov/flu</u>, <u>www.cdc.gov/vaccines</u>, or <u>www.cdc.gov/mmwr</u>.


Michigan Department of Health and Human Services - Division of Immunization

Rev. August 29, 2022



PROPER IM INJECTION TECHNIQUE

- Administer in thickest, most central part of the muscle
- Use needle length based on patient's age and weight
- Insert the needle into the muscle at a 90° angle



https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccineadministration-needle-length.pdf

Image Courtesy of CDC



IMPROPER IM INJECTION TECHNIQUE

- Inflammatory reaction resulting from incorrect administration of a vaccine intended for IM injection in deltoid, into/around the underlying bursa of the shoulder
- Causes shoulder pain and limited range of motion



Images courtesy of CDC



IAC Skills Checklist for Immunization: <u>www.immunize.org/catg.d/p7010.pdf</u>


COADMINISTRATION

- COVID-19 vaccines and other vaccines (i.e., flu) may be administered without regard to timing
 - Simultaneous administration of COVID-19 vaccines on the same day or at any time before or after another vaccine
- Applicable to ALL other vaccines
 - Non-live
 - Live, attenuated

https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html



CDC Vaccine Administration Job Aides





Vaccines must reach the desired tissue to provide an optimal immune response and reduce the likelihood of injection-site reactions. Needle selection should be based on the: Route Age Gender and weight Injection site for adults (19 years and older)

The following table outlines recommended needle gauges and lengths. In addition, clinical judgment should be used when selecting needles to administer injectable vaccines.

Route	Age	Needle gauge and length	Injection site		
Subcutaneous injection	All ages	23–25-gauge 5/8 inch (16 mm)	Thigh for infants younger tha 12 months of age ¹ ; upper outer triceps area for persons 12 months of age and older		
Intramuscular injection	Neonate, 28 days and younger	22–25-gauge 5/8 inch (16 mm²)	Vastus lateralis muscle of anterolateral thigh		
	Infants, 1–12 months	22–25-gauge 1 inch (25 mm)	Vastus lateralis muscle of anterolateral thigh		
		22–25-gauge 1–1.25 inches (25–32 mm)	Vastus lateralis muscle of anterolateral thigh ³		
	Toddlers, 1–2 years	22–25-gauge 5/8 ² –1 inch (16–25 mm)	Deltoid muscle of arm		
		22–25-gauge 5/8 ² –1 inch (16–25 mm)	Deltoid muscle of arm ³		
	Children, 3–10 years	22–25-gauge 1–1.25 inches (25–32 mm)	Vastus lateralis muscle of anterolateral thigh		
	Children, 11–18 years	22–25-gauge 5/8 ² –1 inch (16–25 mm)	Deltoid muscle of arm ^{3,5}		
	Adults, 19 years and older = 130 lbs (60 kg) or less = 130–152 lbs (60–70 kg) Men, 152–260 lbs (70–118 kg) = Women, 152–200 lbs (70–90 kg) = Men, 260 lbs (118 kg) or more = Women, 200 lbs (90 kg) or more	22-25-gauge 1 inch (25 mm ⁴) 1 inch (25 mm) 1-1.5 inches (25-38 mm) 1-1.5 inches (38 mm) 1.5 inches (38 mm)	Deltoid muscle of arm ^{3,5}		


Preferred site

08/04/20

45 mm experts recommend a 5/8-inch peedle for men and women weinhing less than 60 kg. If used, skin must be stretched tightly and subcutageous tissues must not be bunche vastus lateralis muscle in the anterolateral thigh can also be used. Most adolescents and adults will require a 1- to 1.5-inch (25-38 mm) needle to ensure inti

Reference: Advisory Committee on Immunization Practices General Best Practice Guidelines for Immunization

www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html





www.cdc.gov/vaccines/hcp/admin/resource-library.html

FLUVACCINE INFORMATION STATEMENTS (VIS)

- Current IIV/RIV and LAIV VIS edition dates: 8/6/21
- To access Michigan VISs (includes language on MCIR), go to www.michigan.gov/VIS

Soreness, redness, and swelling where the shot is given, fever, muscle aches, and headache can happen after influenza vaccination. (VICP) i There may be a very small increased risk of Galliain-Barré Syndrome (GBS) after inactivated influenza vaccine (the flu shot). death du			The National Vaccine Injury Compensation Program ICP) is a federal program that was created to mpensate people who may have been injured by tain vaccines. Claims regarding alleged injury or ath due to vaccination have a time limit for filing, ich may be as short as two years. Visit the VLCP		or neu	or neuromuscular or metabolic disorders) Does not have a spleen, or has a non-functioning spleen Has a cochlear implant Has a cerebrospinal fluid leak (a leak of the fluid that surrounds the brain to the nose, throat, ear, or some		What if there is a serious problem? allergic reaction could occur after the vaccinated on leaves the clinic. If you see signs of a servere ergic reaction (hives, swelling of the face and throat, culty breathing, a fast heartheat, dizziness, or kness), call 9-1-1 and get the person to the nearest pital.	
		The National (VICP) is a fee compensate pe certain vaccine death due to v			 Has a c Has a c Has a c surrou other la Has ha 				
umococca cine at the ly to have a lth care pro-	VACCI	INE INFORM	ATION STATEMENT		In some postpon For som	VACCINE	INFORMA	TION STATEMEN	Many vaccine information statem
cine has ev ple someti uding vace zy or have	Influenza (Flu) Vacc Recombinant): Wha			Many vaccine information statements ar available in Spanish and other language See www.immurize.org/vis Hojas de información sobre vacunas est disponibles en español y en muchos oth idiomas. Visite www.immurize.org/vis	be more vaccine.	Influenza (Flu) Vaccine What You Need to Kno		Intranasal):	available in Spanish and other las See www.immunize.org/vis Hojas de información sobre vacu disponibles en español y en muci idiomas. Visite www.immunize.or
rith any m vaccine ca	1. Why get vaccinated? Eve		Even when the vaccine	even when the vaccine doesn't exactly match these		1. Why get vaccinated?			ses, and they are always
What if probler Illergic res inated per severe alle and throa	Influenza vaccine can prevent influen Fu is a contagious disease that spread: United States every year, usually betwe and May. Anyone can get the flu, but it dangerous for some people. Infants an children, people 65 years and older, pr and people with certain health conditiv weakened immune system are at great	s around the een October i is more d young egnant people, ons or a	viruses, it may still pro Influenza vaccine does Influenza vaccine may other vaccines. 3. Talk with you care provider	not cause flu. be given at the same time as	Your hes informa 4. Ris - Runny headaa - Vomiti are oth	Influenza vaccine can prevent influenza (flu) Flu is a contagious disease that spreads aroun United States every year, usually between Octo May. Anyone can get the flu, but it is more dar for some people. Infants and young children, p 65 years of age and older, pregnant people, an with certain health conditions or a wakened system are at greatest risk of flu complications	l the ber and gerous veople l people mmune	protect against the influ likely to cause disease ir when the vaccine doesn may still provide some p Influenza vaccine does	
tiness, or w he nearest other sign e provider. verse reactiverse Event lth care pro- dic can do it y www.aers.hb mly for repo- mbers do m	 complications. Pneumonia, bronchitis, sinus infections, and ear infections are examples of flu-related complications. If you have a medical condition, such as heart disease, cancer, or diabetes, flu can make it worse. Flu can cause fever and chills, sore throat, muscle aches, faitue, cough, headche, and runny or stuffy nose. Some people may have vomiting and diarrhea, though this is more common in children than adults. In an average vara, thousands of people in the 	omplications. is heart ke it worse. oat, muscle inny or stuffy and diarrhea, en than adults. le in the more are ions of	Tell your vaccination provider if the person getting the vaccine: Has had an allergic reaction after a previous dose of influenza vaccine, or has any severe, life- threatening allergies • Has ever had Guillain-Barré Syndrome (also called "GBS") In some cases, your health care provider may decide to postpone influenza vaccination until a future visit. Influenza vaccine can be administered at any time during pregnancy. People who are or will be pregnant during influenza season should receive inactivated influenza vaccine.			vaccinat If you have a medical condition, such as heart d As with cancer, or diabetes, flu can make it worse. of a vacc	tions. disease, scle stuffy rrhea, adults. : United alized.	ease, provider Tell your vaccination provider if the person getti the vaccine: east of age its - Is pregnant. Live, attenuated influenza vaccine recommended for pregnant people + Has had an allergic reaction after a previous of influenza vaccine, or has any severe, life three allergies - Is a child or adolescent 2 through 17 years of	
	illnesses and flu-related visits to the do 2. Influenza vaccines	doctor each year. People with minor illn vaccinated. People who should usually wait un		vaccine. nesses, such as a cold, may be ho are moderately or severely ill ntil they recover before getting		2. Live, attenuated influenza vaccine		containing products • Has a weakened imm	une system years old who has asthr
accine Info nactiva	CDC recommends everyone 6 months and older get vaccinated every flu season. Children 6 months through 8 years of age may need 2 dosse sturing a single flu season. Everyone else needs only 1 dose each flu season. It takes about 2 weeks for protection to develop		influenza vaccine. Your health care provider can give you more information.		Vaccine Live	get vaccinated every flu season. Children 6 m through 8 years of age may need 2 doses duri single flu season. Everyone else needs only 1 d flu season. Live, attenuated influenza vaccine (called "LAI nasal spray vaccine that may be given to non-	nths 'Is 5 years or older and has a g a 'Has taken influenza antivir see ach 3 weeks 'Cares for severely immuno who require a protected envi ''') is a 'Has other underking medi		d has asthma intiviral medication in t munocompromised peo ed environment medical conditions that
	after vaccination. There are many flu viruses, and they ar changing. Each year a new flu vaccine protect against the influenza viruses be likely to cause disease in the upcoming	is made to elieved to be	(Je constant)	U.S. Department of Health and Human Services Centers for Discase Control and Prevention		people 2 through 49 years of age. It takes about 2 weeks for protection to develo after vaccination.	p		heart disease, kidney di U.S. Department of Health and Human Service Conters for Disease Control and Prevention



Don't forget to submit your questions in the Questions and Answers box!

TREATMENT OF INFLUENZA

TREATING CASES OF INFLUENZA PRESCRIBING ANTIVIRALS



TREATMENT FOR PATIENTS WITH INFLUENZA

- Antiviral treatment is recommended as soon as possible for any patient with suspected or confirmed flu who:
 - Is hospitalized
 - Has severe, complicated, or progressive illness
 - Is at higher risk for flu complications
- Decision to start antiviral treatment should not wait for lab confirmation of flu
- Clinical benefit is greatest when treatment is administered early, within 48 hours of illness onset
 - Antivirals can be prescribed to persons with illness onset greater than 48 hours
- A history of flu vaccination does not rule out the possibility of influenza infection or the need to use antivirals to treat flu

www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm

WHO SHOULD BETREATED WITH FLU ANTIVIRALS?

- Children younger than 2 years, adults 65 years and older
- Persons with chronic pulmonary, cardiovascular, renal, hepatic, hematological, and metabolic disorders, or neurologic and neurodevelopment conditions
- Persons with immunosuppression, including caused by medications or HIV infection
- Persons who are pregnant or postpartum (within 2 weeks of delivery)
- Younger than 19 years on long-term aspirin or salicylate therapy
- American Indians and Alaska Natives
- BMI ≥ 40
- Residents of nursing homes and other chronic care facilities



ANTIVIRAL AGENT	USE	RECOMMENDED FOR	NOT RECOMMENDED FOR USE IN
Oseltamivir/Tamiflu®	Treatment	Any age	N/A
(oral)	Chemoprophylaxis	3 months & older	N/A
Zanamivir/Relenza®	Treatment	7 years & older	People with underlying respiratory disease (e.g., asthma, COPD)
(inhaled)	Chemoprophylaxis	5 years & older	People with underlying respiratory disease (e.g., asthma, COPD)
Peramivir/Rapivab®	Treatment	6 months & older	N/A
(IV)	Chemoprophylaxis	Not recommended	N/A
	Treatment	5 years & older	N/A
Baloxavir/Xofluza® (oral)	Chemoprophylaxis	Approved for post-exposure prophylaxis in persons 5 years and older	N/A



www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm

Don't forget to submit your questions in the Questions and Answers box!

FLU VACCINE CONSIDERATIONS DURING COVID-19



Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Summary of recent changes (last updated August 22, 2022):

- Guidance for primary series vaccination using Novavax COVID-19 Vaccine in adolescents ages 12–17 years
- Reorganization of Janssen COVID-19 Vaccine guidance into an appendix

Reference Materials

- <u>Summary Document for Interim Clinical Considerations</u> (Updated 6/24/2022)
- Interim COVID-19 Immunization Schedule (Updated 6/24/2022)
- <u>At-A-Glance COVID-19 Vaccination Schedule</u> (Updated 8/22/2022)
- Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group
- <u>Pfizer-BioNTech for Children who Transition from a Younger to Older Age</u>
 Group

Get Email Updates

Receive email updates about this page.

<u>What's this?</u>


Get Email Updates

COVID-19 Vaccines, Recommendations, and Schedules				
COVID-19 vaccination overview People who are not immunocompromised People who are immunocompromised	Timing, spacing, and interchangeability Patient counseling Laboratory testing			
Safety				
Contraindications and precautions Reporting of adverse events	Safety considerations for mRNA COVID-19 vaccines: Moderna and Pfizer-BioNTech Safety considerations for Novavax COVID-19 Vaccine COVID-19 vaccination and myocarditis and pericarditis			
Special Situations and Populations				
COVID-19 vaccination and SARS-CoV-2 infection COVID-19 vaccination and MIS-C and MIS-A	Pregnancy, lactation, and fertility Other special populations			



Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

COVID-19 Vaccine Provider Guidance and Educational Resources



This webpage will house materials to support COVID-19 Vaccine Providers in successful implementation of the COVID-19 Vaccination Program. Be sure to "bookmark" this page and check back frequently for updates!

GENERAL COVID-19 VACCINE RESOURCES

Increasing Access to Vaccine Opportunities: Recommendations for Health Care Providers - Updated 6/18/21

COVID-19 Vaccines During Hospital Stays and Medical Appointments - Updated 6/14/21

COVID-19 Vaccination Clinic Preparation Checklist & Resource Toolkit - Updated 5/28/21

ACIP Recommendations for COVID-19 Vaccine

Interim Clinical Considerations for COVID-19 Vaccine

CDC COVID-19 Vaccine Resources for Healthcare Professionals

· Vaccine administration, storage and handing, reporting, and patient education for each specific vaccine

COVID-19 Vaccine Training Module

· Self-paced module with certificate of completion (no CE)

MDHHS strongly recommends that all COVID-19 Vaccine Providers complete this training.

CDC HCP Vaccine Administration Resource Library

CONTENT-SPECIFIC COVID-19 RESOURCES

Webinars

Upcoming Noontime Knowledge: Thursday July 1, 2021 at 12:00 pm

Education Corner

Enrollment

Redistribution

Vaccine Billing and Vaccine Code Sets

MDHHS COVID-19 Provider Guidance and Education Website

www.michigan.gov/covidvaccineprovider




Don't forget to submit your questions in the Questions and Answers box!

INFLUENZA VACCINATION COVERAGE LEVELS AND STRATEGIES TO INCREASE COVERAGE



MICHIGAN INFLUENZA VACCINATION COVERAGE, SELECT AGES, ACCORDING TO NATIONAL SURVEYS AND MCIR, 2013-2021



- Minimal improvement over 8 season
- "Everyone, every year"
 - Overall MCIR coverage remains < 50%
 - National Estimates 57%
- Healthy People 2030 goals
 - 70% for healthy adults (18+ years) and children 6 months through 17 years of age
- MCIR estimates below national estimates for MI coverage



FOCUS AREA #1: 2-DOSE COVERAGE

- 2021-22 coverage levels in Michigan children, MCIR data
- Children 6 months through 8 years of age complete (1 or 2 doses)
 - Only 26.8% complete for the season (I or 2 doses) (280,423/1,044,486)
 - County Range: 6.9% 44.4%
- Of the 541,402 children recommended 2 doses
 - 8.8% (47,844) received both doses
 - County range: 1.2% 18.1%



METHODS TO IMPROVE FLU COVERAGE IN YOUNG CHILDREN

- Initiate the conversation with parents/patients about the importance of flu vaccine
 - Tell a personal story
 - Alana's Foundation: <u>www.alanasfoundation.org/</u>
 - Families Fighting Flu: <u>www.familiesfightingflu.org/</u>
- Ensure children who need 2 doses get their first dose early
- No missed opportunities
 - Assess patients during every visit
 - Provide a strong recommendation and offer flu vaccine to every patient

- Routine vaccination hesitancy¹: 6%
- Hesitancy for flu vaccine: 26%
- Parent hesitation²:
 - Perceived low vaccine effectiveness
 - Safety concerns
 - Perception that flu vaccine causes the flu




- 1. Kempe, A. et al., Pediatrics, 2020 Retrieved from https://doi.org/10.1542/peds.2019-3852
- 2. De St. Maurice, A. et al., Pediatrics, 2020 Retrieved from https://doi.org/10.1542/peds.2020-1770
- 3. MDHHS Clearinghouse: <u>www.healthymichigan.com</u>

FOCUS AREA #2: PREGNANT PEOPLE

- Among persons pregnant anytime during October 2020–January 2021, 54.5% reported receiving a dose of flu vaccine since July 1, 2020
- Pregnancy Risk Assessment Monitoring System (PRAMS)
 - 53.7% coverage Michigan²
 - 35.4% among NH-Black individuals
 - 58.9% among NH-White individuals

Flu Shot in 12 Months Before Delivery by Maternal Race | Ethnicity | Ancestry MI PRAMS 2016-2019






I. www.cdc.gov/mmwr/volumes/68/wr/mm6840e1.htm

2. PRAMS data provided by P.I- Peterson Haak, MDHHS

METHODS TO IMPROVE COVERAGE IN PREGNANT PEOPLE

- Assure you are giving a strong recommendation
- AIMS Method²:
 - Announce: vaccination will happen, assume they are ready to vaccinate
 - Inquire: seek to understand the person by asking about their concerns
 - Mirror: make sure they know you understand their concerns by mirroring but not repeating and asking questions
 - Secure: consolidate every conversation by securing their trust





Protect yourself and your baby. Get your flu and Tdap vaccine during each pregnancy.

Vaccines given during pregnancy can help protect your baby from serious diseases during the first few months after birth!

Flu vaccine can be given at any time during pregnancy. Tdap vaccine should be given in the early part of the 3rd trimester.

Talk to your health care provider today!

Protect Yourself and Your Baby. Get Your Flu Vaccine!

Flu is a serious disease for infants and pregnant women

Pregnant women who get the flu are at an increased risk of hospitalizations and having premature labor and delivery.

Flu vaccine offers the best protection against seasonal flu

Your flu vaccine helps protect your baby against the flu for up to 6 months after birth.

Infants of mothers vaccinated against influenza are up to 48 percent less likely to be hospitalized with flu-related complications compared to infants of mothers who were not vaccinated against flu*.

*Poehling et al. American journal of Obstetrics and Gynecology, (2005)

Vaccines during pregnancy are safe and effective

Flu vaccine is the single best way to prevent the flu.

You can get a flu shot at any time during your pregnancy, and it is covered by insurance.

A recent study found that the flu shot can reduce the risk of influenza-associated hospitalizations during pregnancy by 40 percent*.

*Thompson et al. Clinical Infectious Diseases, (2019)

Surround your baby with vaccinated people

Infants cannot get the flu vaccine until they are 6 months old.

The best way to protect infants is to vaccinate those around them including parents, siblings, grandparents, child care workers, and health care personnel.





Only 50 percent of pregnant women get their flu shot each year - time to bump it up!

Talk to your healthcare provider today about all vaccines needed during pregnancy to protect you and your baby.

For more information visit:

- michigan.gov/flu
- cdc.gov/flu

immunizationforwomen.org
 ivaccinate.org





57

Revised June 2019

FOCUS AREA #3: UNDERLYING MEDICAL CONDITIONS AND RACIAL/ETHNIC DISPARITIES

- Persons of any age
 - Diabetes, asthma, heart disease, neurological conditions, and more²
- Racial/ethnic disparities observed in persons with chronic conditions
- American Indian/Alaskan Native (Al/AN) seem to be at higher risk for flu complications

<u>www.cdc.gov/flu/fluvaxview/coverage-2021estimates.htm</u>
 <u>www.cdc.gov/flu/about/disease/high_risk.htm</u>

Flu Vaccination Coverage by Race/Ethnicity, Children and Adults, US, MI, 2020-2021 Season¹

	US Children (6 mos- 17 yrs)	US Adults (18+ yrs)	All persons MI (6 mos +)
Non-Hispanic White	60.4	55.5	57.2
Non-Hispanic Black	49.1	40.4	35.9
Hispanic	58.8	38.6	49.4
Asian	69.2	54.5	-
AI/AN	48.3	41.5	-
Other/Multiple	57.8	48.7	51.4



ADDRESSING CHRONIC CONDITIONS AND DISPARITIES

- Disparities result from individual attitudes and beliefs, social norms, and health care practices¹
 - Engagement is critical
 - Tailor messages to your audience
 - Leverage local capacity
 - Translated materials
 - Culturally appropriate education
- CDC materials addressing specific chronic conditions²
- HCP Toolkit³

2.




- www.ncbi.nlm.nih.gov/pubmed/28933619
- www.cdc.gov/vaccines/hcp/adults/for-patients/health-conditions.html
- 3. www.cdc.gov/flu/professionals/vaccination/prepare-practice-tools.htm

Information Series for Adults What You Need to Know About Diabetes and Adult Vaccines

Each year thousands of adults in the United States get sick from diseases that could be prevented by vaccines — some people are hospitalized, and some even die. People with diabetes (both type 1 and type 2) are at higher risk for serious problems from certain vaccine-preventable diseases. Getting vaccinated is an important step in staying healthy.

Why Vaccines Are Important for You

Diabetes, even if well managed, can make it harder for your immune system to fight infections. If you have diabetes, you may be at risk for more serious complications from an illness compared to people without diabetes.



- People with diabetes have higher rates of hepatitis B than the rest of the population. Outbreaks of hepatitis B associated with blood glucose monitoring procedures (blood sugar meters, finger stick devices, and other equipment such as insulin pens) have happened among people with diabetes.
- People with diabetes are at increased risk for death from pneumonia (lung infection), bacteremia (blood infection), and meningitis (infection of the lining of the brain and spinal cord).

Immunization provides the best protection against vaccine-

preventable diseases

Vaccines are one of the safest ways for you to protect your health, even if

you are taking prescription medications to control your diabetes.

Vaccine side effects are usually mild and go away on their own. Severe side effects are very rare.

Getting Vaccinated

You regularly see your provider for diabetes care, and that is a great place to start! If your healthcare professional does not offer the vaccines you need, ask for a referral so you can get the vaccines elsewhere.

Adults can get vaccines at doctors' offices, pharmacies, workplaces, community health clinics, health departments, and other locations. To find a place near you to get a vaccine, go to http://vaccine.healthmap.org.

Most health insurance plans cover recommended vaccines. Check with your insurance provider for details and for a list of vaccine providers covered by your plan. If you do not have health insurance, visit <u>www.healthcare.gov</u> to learn more about health insurance options.

For more information on vaccines or to take an adult vaccine quiz to find out which vaccines you might need, visit <u>www.cdc.gov/vaccines/adults</u>. cs258091C



What vaccines do you need?

Flu vaccine every year to protect against seasonal flu

Pneumococcal vaccines to protect against serious pneumococcal diseases

Hepatitis B vaccine series to protect against hepatitis B

Tdap vaccine to protect against tetanus, diphtheria, and pertussis (whooping cough)

Zoster vaccine to protect against shingles if you are 50 years or older

There may be other vaccines recommended for you so be sure to talk with your healthcare professional about what is right for you.



AND REMEMBER

I won't spread flu to my patients or my family.

Even healthy people can get the flu, and it can be serious.

Everyone 6 months and older should get a flu vaccine. This means you.

This season, protect yourself-and those around youby getting a flu vaccine.

CHHC

For more information, visit: http://www.cdc.gov/flu

For office use



ol and Preventi

RESOURCES THROUGHOUT THE SEASON

- **MI Flu Focus**
 - Weekly flu updates during the flu season
 - Includes surveillance system updates, flu updates of interest, flu journal articles, and other flu news
 - To receive MI Flu Focus email Shelly Doebler (<u>DoeblerM@michigan.gov</u>) with the subject line MI Flu Focus
- Seasonal Flu Posters:
 - Order free at: <u>www.healthymichigan.com</u>



Michigan Flu Focus

Weekly Influenza Surveillance Report

August 19, 2022

Novel Influenza A Viruses

Nationally, 8 human infections

with a variant influenza A virus

(2 H1N2v, 4 H3N2v, 1 H1v,

1 H5) were reported for the

For more information, visit the CDC

Toolkit will help LHDs in planning

for and responding to suspected

influenza outbreaks associated

with swine at agricultural fairs

Swine Variant Influenza Toolkit

Templates Document

Swine Variant Influenza Toolkit

The Swine Variant Influenza

2021-2022 season.

FluView Interactive

and exhibits. See:

•

Vol. 19; No. 37

Week Ending August 13, 2022 | WEEK 32

Editor: Sue Kim Editor email: KimS2@michigan.gov

Michigan 2021-2022

Season Overview

Note: Most systems were impacted by the COVID-19 pandemic and should be interpreted with caution. Geographic Spread - reporting for this system was suspended for the 2021-2022 season due to the impact of the COVID-19 pandemic on ILI activity. Outbreaks - 35 (18C, 4N, 8SE, 5SW) flu outbreaks were reported during the 2021-2022 season. Sentinel Provider Surveillance (ILINet) - provisional

data shows ILI activity remained below the regional baseline of 2.5% all season. Laboratory – 544 flu positive results (541 A, 3 B) were reported by the MDHHS Bureau of Labs. Hospitalizations - 260 (61 pediatric, 199 adult) flu

hospitalizations were reported in the catchment area from October 1, 2021 to June 11, 2022. Pediatric flu mortality - One (1) pediatric influenza

death (A/H3 virus) has been confirmed by MDHHS.

Updates of Interest

CDC Confirms First Human Infections with Flu Virus from Pigs During 2022 - CDC has reported the first three human infections with a variant influenza A virus. H3N2v, in 2022. The variant flu virus infections were reported by West Virginia and among attendees of the same agricultural fair where pigs tested positive for swine influenza A(H3N2) virus. All three human infections were in people younger than 18 years and two of the three infected people had direct contact with pigs.

Flu Bytes

Alana's Foundation Prepares for 9th Annual National College & University Flu Challenge

Alana's Foundation is once again teaming up with colleges and universities across the nation for the 2022-2023 College & University Flu Vaccination Challenge to increase flu vaccination rates among college-aged young adults through friendly competition.

Small, medium, and large institutions are encouraged to participate. Alumni, faculty, staff, and fans of participating schools are also eligible to help their school win. The number of flu vaccine doses administered will be reported through a simple self-report survey by each school. Vaccine Assistance Grants are also available for participating schools to purchase vaccines for underinsured and uninsured students.

Institutions in each size category with the greatest number of flu vaccine doses administered at their campus health center and/or campus flu clinics during the challenge will earn bragging rights as well as the honor of displaying the Alana Yaksich Memorial traveling trophy. In 2021, over 30,000 doses were administered through the challenge. More information can be found here.

Influenza News Blast


- STUDY: Importance of Continued Efforts to Prevent and Attenuate Influenza in Children
- Researchers getting closer to a "universal" flu vaccine

Influenza

2022-2023 Flu Vaccine

Doses by Vaccine Weekly Coverage Doses Goals Doses by County Coverage by County Seasonal Coverage Learn More Data as of : Weekly Influenza Vaccination Coverage by Age 6/30/22 Based on data reported to Michigan's immunization registry, the Michigan Care Improvement Registry (MCIR). The influenza week corresponds to the number of weeks since the flu season began on July 1. County Month Influenza Vaccination Coverage by Age Group All \sim All Influenza Season 60% 2019-20 Age Group 02020-21 40% 2021-22 All $\mathbf{\nabla}$ 20% Influenza Week The best way to protect yourself from the seasonal state and it is more important than ever to stay he 1 53 0% Flu vaccines are typically available in September ar 6 months through 5 through 12 13 through 17 18 through 24 25 through 49 50 through 64 65 years and older 4 years years years years years years

Influenza Vaccination Coverage by Week



www.Michigan.gov/flu

HEALTH PROFESSIONAL RESOURCES

2020-21 Influenza Vaccine Updates

FLU BASICS

- Quick Look at 2020-21 Recombinant Influenza Vaccine (RIV4) (NEW 8/28/20)
- Quick Look at 2020-21 Cell Culture-based IIV (ccIIV4) (NEW 8/28/20)
- Quick Look at 2020-21 Live Attenuated Influenza Vaccine (LAIV4) (UPDATED 8/28/20)
- Quick Look at 2020-21 Inactivated Influenza Vaccines: IIV4, HD-IIV4, aIIV3, aIIV4 (UPDATED 8/28/20)
- •Administering 2020-21 Influenza Vaccines: IM and IN (UPDATED 8/28/20)
- 2020-21 Seasonal Influenza Vaccine Dose Volumes for Children (UPDATED 8/28/20)
- •2020-21 Seasonal Influenza Vaccine Presentation Chart (UPDATED 8/28/20)
- Who Needs 2 Doses of 2020-21 Seasonal Influenza Vaccine? (UPDATED 8/24/20)
- •2020-21 Vaccines for Children (VFC) Influenza Vaccine (UPDATED 8/24/20)
- •2020-21 Flu Vaccine for Persons who Report Egg Allergy (UPDATED 8/24/20)
- •Influenza Vaccine Frequently Asked Questions (FAQ) (12/4/19)
- 2019-20 LAIV Key Points for Patients (8/29/19)
- •2019-20 LAIV Key Points for Providers (8/29/19)
- Flu and Pregnancy Posters
- Got Flu Vaccine? Posters
- Remember to use Michigan versions of Vaccine Information Statements


*General Public Resources Coming Soon

Go to <u>www.Michigan.gov/flu</u> and click on Resources → Resources for Health Professionals to find all our updated handouts!



Q AND A SESSION

 Please type your questions in the Questions and Answers Box.





TO OBTAIN MPA CPE CREDIT

- Complete post-test and evaluation by September 25, 2022, at https://www.lecturepanda.com/a/PediatricandAdultInfluenzaWebinar2022-2023FluSeason
- Participants must pass the posttest with 70% or higher
- This link will be provided to all pharmacist registrants after the webinar.
- When completing the program evaluations and posttests, you will be required to provide your CPE Monitor ID number. Register at <u>www.MyCPEMonitor.net</u>



THANK YOU FOR YOUR ATTENDANCE!

- A survey link will be sent out to all registrants
- Physicians/nurses, to obtain I AMA PRA Category I Credit for participating today:
 - Complete the post-test within MSU's evaluation by logging in to <u>https://cmetracker.net/MSU</u>
 - Needs to be completed by October 6, 2022
 - If you have any questions, contact Connie DeMars at <u>demars@msu.edu</u>
- If we don't have time to address your questions:
 - Andrea Becker: <u>BeckerAI@Michigan.gov</u>
 - Michelle Doebler: <u>DoeblerM@Michigan.gov</u>

The webinar recording & slides will be posted soon for **2 weeks only** at <u>www.michigan.gov/flu</u> \rightarrow Resources \rightarrow Health Professionals Resources. Check that site frequently! ₆₆

